PT  - JOURNAL ARTICLE
AU  - Ping Lu
AU  - Michael L. Schrag
AU  - Donald E. Slaughter
AU  - Conrad E. Raab
AU  - Magang Shou
AU  - A. David Rodrigues
TI  - MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR
AID  - 10.1124/dmd.31.11.1352
DP  - 2003 Nov 01
TA  - Drug Metabolism and Disposition
PG  - 1352--1360
VI  - 31
IP  - 11
4099  - http://dmd.aspetjournals.org/content/31/11/1352.short
4100  - http://dmd.aspetjournals.org/content/31/11/1352.full
SO  - Drug Metab Dispos2003 Nov 01; 31
AB  - Zileuton, a 5-lipoxygenase inhibitor, was evaluated as an inhibitor of cytochrome P450 activity in human liver microsomes. In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 μM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6α-hydroxylation (CYP2C8), diclofenac 4′-hydroxylation (CYP2C9), (S)-mephenytoin 4′-hydroxylation (CYP2C19), bufuralol 1′-hydroxylation (CYP2D6), testosterone 6β-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6). When preincubated with NADPH-fortified human liver microsomes in the absence of substrate, zileuton (racemate) was shown to inhibit POD. The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min-1 and 117 μM, respectively (kinact/KIratio of 0.0003 min-1 μM-1). Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min-1, KI, 98.2 μM, kinact/KIratio, 0.0004 min-1 μM-1; (R)-(+)-zileuton; kinact, 0.012 min-1, KI, 66.6 μM, kinact/KIratio, 0.0002 min-1 μM-1]. In addition, the inhibition of CYP1A2 was not reversed in the presence of reduced glutathione, catalase, and superoxide dismutase and was refractory to dialysis. Therefore, zileuton was characterized as a mechanism-based inhibitor of human liver microsomal CYP1A2. Mechanism-based inhibition of CYP1A2 may explain why zileuton decreases the oral clearance of antipyrine, propranolol, (R)-warfarin, and theophylline, at doses that have a minimal effect on the pharmacokinetics of (S)-warfarin, phenytoin, and terfenadine. The American Society for Pharmacology and Experimental Therapeutics